Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 10—October 2022
Research Letter

Rickettsial Infections Causing Acute Febrile Illness in Urban Slums, Brazil

John B. Fournier1, Lucas S. Blanton1, Nivison Nery, Elsio A. Wunder, Federico Costa, Mitermayer G. Reis, Guilherme S. Ribeiro, David H. Walker, and Albert I. KoComments to Author 
Author affiliations: Yale School of Public Health, New Haven, Connecticut, USA (J.B. Fournier, E.A. Wunder Jr., F. Costa, M.G. Reis, A.I. Ko); University of Texas Medical Branch, Galveston, Texas, USA (L.S. Blanton, D.H. Walker); Fundação Oswaldo Cruz, Salvador, Brazil (N. Nery Jr., F. Costa, M.G. Reis, G.S. Ribeiro, A.I. Ko); Universidade Federal da Bahia, Salvador (N. Nery Jr., F. Costa, M.G. Reis, G.S. Ribeiro)

Main Article

Table

Clinical characteristics of 7 patients and IFA serum titers for SFGR or TGR IgG reactivity in study of rickettsial infections causing acute febrile illness in urban slums, Brazil*

Patient no. Age, y/sex Symptoms Duration of illness, d† Antigen (group) IFA titers
Acute phase‡ Convalescent phase§
1 10/F Fever, headache, myalgia 6 R. rickettsii (SFGR) 0 256
2 21/F Fever, headache, myalgia 1 R. rickettsii (SFGR) 0 256
3 42/F Fever, headache, myalgia, lethargy, diarrhea 3 R. rickettsii (SFGR) 0 256
4 6/M Fever, headache, myalgia, lethargy, vomiting, diarrhea 10 R. rickettsii (SFGR) 0 128
5 8/F Fever, headache, myalgia, fatigue, vomiting, diarrhea 6 R. rickettsii (SFGR) 0 256
6 12/M Fever, headache 1 R. rickettsii (SFGR) 128 512
7 6/F Fever, lethargy, diarrhea 5 R. typhi (TGR) 0 256

*Rickettsia rickettsii Sheila Smith strain was used to determine SFGR IgG reactivity and R. typhi Wilmington strain was used to determine TGR IgG reactivity. IFA, immunofluorescence assay; SFGR, spotted fever group rickettsiae; TGR, typhus group rickettsiae. †Number of days of illness before attending urgent care facility in Salvador, Brazil. ‡Acute-phase serum samples were obtained at the time of enrollment when the patient arrived initially at the urgent care facility. §Convalescent-phase serum samples were obtained >15 d after enrollment in the study.

Main Article

1These authors contributed equally to this article.

Page created: August 30, 2022
Page updated: September 21, 2022
Page reviewed: September 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external